Adrenocortical Carcinoma Drugs Market Will Generate Record Revenue by 2029
Adrenocortical carcinoma drugs market is anticipated to grow at a significant CAGR during the forecast period. One of the key factors that are primarily driving the growth of the market includes the comparative advantages of novel drugs over chemotherapeutics. Chemotherapeutics such as mitotane can cause major side effects including peripheral neuropathy and seizures. This is expected to increase the use of novel drugs, which show long-term efficacy and potential benefits in patients.
Another key factor driving the market growth
includes the rising advancements in imaging techniques for detecting tumors and
adrenal lesions. Various imaging techniques with enhanced diagnostic accuracy
as a non-invasive approach have been developed for adrenocortical carcinoma. For
instance, the multiphase computed tomography technique is one of the latest
imaging techniques which can calculate both the absolute percentage and the
relative percentage washout, which helps in identifying both benign and
malignant lesions of the adrenal gland. Thus, advances in imaging techniques
for adrenal tumors is anticipated to fuel the growth of the global
adrenocortical carcinoma drugs market during the forecast period.
Some key players operating in the market include
Bristol-Myers Squibb Co., Merck & Co., Inc., and Laboratoire
HRA-Pharma SAS, among others. These players are eyeing on strengthening their
position in the market by adopting various strategies as mergers and
acquisitions, partnerships, collaborations, new product launch and development
in the existing product portfolio, and so on. For instance, in November 2021,
Merck announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has been approved by
the Japan Pharmaceuticals and Medical Devices Agency (PMDA) for the first-line
treatment of patients with radically unresectable, advanced or recurrent
esophageal carcinoma in combination with chemotherapy (5-fluorouracil [5-FU]
plus cisplatin) based on data from the Phase 3 KEYNOTE-590 trial.
To Request a Sample of our Report on Adrenocortical
Carcinoma Drugs Market: https://www.omrglobal.com/request-sample/adrenocortical-carcinoma-drugs-market
Market Coverage
·
The market number available for – 2021-2029
·
Base year- 2021
·
Forecast period- 2023-2029
·
Segment Covered
·
Regions Covered- Globally
Competitive Landscape: Bristol-Myers Squibb Co., Merck & Co.,
Inc., and Laboratoire HRA-Pharma SAS, among others.
Adrenocortical Carcinoma Drugs Market by Segment
By Type
•
Chemotherapy
•
Targeted therapy
By Application
•
Hospital
•
Research Institute
•
Clinic
•
Other
A
full Report of Adrenocortical Carcinoma Drugs Market is Available @ https://www.omrglobal.com/industry-reports/adrenocortical-carcinoma-drugs-market
Adrenocortical Carcinoma Drugs Market by Region
· United
States
· Canada
Europe
· UK
· Germany
· Spain
· France
· Italy
· Rest
of Europe
Asia-Pacific
· India
· China
· Japan
· South
Korea
· Rest
of APAC
Rest of the World
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
For More Customized Data,
Request for Report Customization @ https://www.omrglobal.com/report-customization/adrenocortical-carcinoma-drugs-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment